A Phase 1/2 Study Evaluating the Safety, Pharmacokinetics and Efficacy of ABT-414 in Subjects With Advanced Solid Tumours Likely to Over-Express the Epidermal Growth Factor Receptor (EGFR)

Trial Profile

A Phase 1/2 Study Evaluating the Safety, Pharmacokinetics and Efficacy of ABT-414 in Subjects With Advanced Solid Tumours Likely to Over-Express the Epidermal Growth Factor Receptor (EGFR)

Completed
Phase of Trial: Phase I/II

Latest Information Update: 13 Mar 2018

At a glance

  • Drugs Depatuxizumab mafodotin (Primary)
  • Indications Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions; First in man; Pharmacokinetics; Therapeutic Use
  • Sponsors AbbVie
  • Most Recent Events

    • 13 Mar 2018 According to results published in the Cancer, study was designed as a phase 1 and 2 however, the study sponsor ultimately decided not to extend the study into the phase 2 expansion cohort, and no patients were enrolled in that phase.
    • 13 Mar 2018 Results assessing the safety, pharmacokinetics, and efficacy of depatux-m in patients who had advanced solid tumors, were published in the Cancer.
    • 07 Jan 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top